[Management of Dermatologic Toxicities Related to Immune Checkpoint Inhibitors]

Zhongguo Fei Ai Za Zhi. 2019 Oct 20;22(10):639-644. doi: 10.3779/j.issn.1009-3419.2019.10.06.
[Article in Chinese]

Abstract

Immune checkpoint inhibitors (ICIs) represent a major breakthrough in cancer therapy. Immune-related adverse events (irAEs) may occur during treatment due to their unique mechanism of action. Dermatologic toxicities appear to be one of the most prevalent irAEs. The most common symptoms are maculopapular rash and pruritus. Serious dermatologic AEs, including Stevens-Johnson syndrome and toxic epidermal necrolysis, are rare. In this review, we summarized guidelines of management of immunotherapy-related toxicities and case reports, and proposed treatment recommendation.

【中文题目:免疫检查点抑制剂相关皮肤不良反应诊治建议】 【中文摘要:免疫检查点抑制剂已应用于多种恶性肿瘤的治疗。免疫检查点抑制剂会引起免疫相关不良反应,其中皮肤不良反应是常见的不良反应之一。皮肤不良反应最常表现为斑丘疹和瘙痒。严重的皮肤不良反应包括Stevens-Johnson综合征、中毒性表皮坏死松解症等。本文综合各个免疫治疗相关不良反应管理指南、皮肤不良反应个案报道及综述,并结合临床实践,提出了免疫相关皮肤不良反应的诊治建议。】 【中文关键词:免疫检查点抑制剂;免疫相关不良反应;皮肤不良反应】.

Keywords: Dermatologic toxicities; Immune checkpoint inhibitor; Immunotherapy-related toxicities.

Publication types

  • Review

MeSH terms

  • Humans
  • Immunotherapy / adverse effects*
  • Neoplasms / drug therapy
  • Neoplasms / immunology
  • Skin / drug effects*

Grants and funding

本文受中国医学科学院医学与健康科技创新工程项目(No.2016-I2M-1-002)